Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922205 | 0.85 | RPS6KB1 (0.45) | MAPTRPS6KB1LMNATP53MEN1 | |
| SCHEMBL4931225 | 0.85 | RPS6KB1 (0.55) | MAPTRPS6KB1 | |
| SCHEMBL4922386 | 0.82 | RPS6KB1 (0.45) | MAPTRPS6KB1LMNATP53 | |
| SCHEMBL4921827 | 0.81 | RPS6KB1 (0.50) | MAPTRPS6KB1LMNATP53 | |
| SCHEMBL4923215 | 0.81 | RPS6KB1 (0.52) | MAPTRPS6KB1LMNA | |
| SCHEMBL4928666 | 0.81 | RPS6KB1 (0.46) | MAPTRPS6KB1LMNATP53ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4933444 | 0.79 | RPS6KB1 (0.51) | MAPTRPS6KB1TP53GSK3BALDH1A1 | |
| SCHEMBL4930049 | 0.79 | RPS6KB1 (0.44) | MAPTRPS6KB1LMNATP53 | |
| SCHEMBL4931678 | 0.79 | RPS6KB1 (0.49) | RPS6KB1ALDH1A1 | |
| SCHEMBL4931171 | 0.78 | RPS6KB1 (0.51) | MAPTRPS6KB1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | MAPT 4051/4885RPS6KB1 13/4885LMNA 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.